Ella Fitzgerald always loved Paris in the springtime, and the Drug Information Association (DIA) is now hoping the French capital will prove to be an irresistible lure for the pharmaceutical industry. For the 27th DIA Annual EuroMeeting, organizers have switched the event from its usual late March slot to mid-April in 2015.
The congress will look at some of the major challenges facing global health today, including the need to come together to drive innovation. The opportunity of the Innovative Medicines Initiatives (IMI) and other public-private partnerships are formative mechanisms that must be maximized in Europe and other regions, program chairs note.
Discussion at the meeting will concentrate on how early and harmonized regulatory dialogue is necessary to ensure clinical development that is more efficient and will accelerate access to novel therapies for patients. The role of the European Union's new clinical trials legislation will come under scrutiny in the meeting's opening track on access to innovative treatments.
Another track will look at special development pathways in pediatrics, the elderly, and in pregnancy. Nearly 10 years after the adoption of the Paediatric Regulation, substantial experience has been gained, yet science continues to evolve in this area and raises new questions to be answered in the future. At the same time, the need for global convergence has become evident in several areas. Also, the speed of traditional development concepts is slower than the speed of ageing in European society, according to the theme leaders.
Further parallel sessions will focus on innovation in vaccine development, medical devices, and combination products, novel treatments for rare diseases, availability of medicinal products/drug shortages, pharmacovigilance, big data, and mobile health, among other areas.
Paris has a rich history of medical innovation. Local scientists and clinicians have changed modern medicine through the discovery of instruments such as the stethoscope and hypodermic needle, treatments like antibiotics or antipsychotics, vaccines against tuberculosis and rabies, and the discovery of diseases such as HIV.
-Philip Ward
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.